cefepime + vancomycin

Cefepime + vancomycin is a combination of two intravenous antibiotics commonly used in hospital settings for the empirical treatment of severe infections, including sepsis and hospital-acquired pneumonia. Cefepime is a fourth-generation cephalosporin (beta-lactam) antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis and death. Vancomycin is a glycopeptide antibiotic that inhibits cell wall synthesis in Gram-positive bacteria by binding to the D-Ala-D-Ala terminus of peptidoglycan precursors, preventing cross-linking and resulting in bacterial death[6]. This combination provides broad-spectrum coverage against both Gram-negative (cefepime) and Gram-positive organisms (vancomycin), including methicillin-resistant Staphylococcus aureus (MRSA). The drugs are physically and chemically compatible for co-administration via Y-site infusion[2][4], but their combined use increases the risk of nephrotoxicity compared to some other regimens[1][8].

Brand names

MaxipimeVancocin

Other names

cefepime and vancomycinvancomycin and cefepime